Monoclonal Antibody to O-Acetyl-GD2 Ganglioside Shows Anti-Tumor Activity
Author Information
Author(s): Alvarez-Rueda Nidia, Desselle Ariane, Cochonneau Denis, Chaumette Tanguy, Clemenceau Béatrice, Leprieur Stéphanie, Bougras Gwenola, Supiot Stéphane, Mussini Jean-Marie, Barbet Jacques, Saba Julie, Paris François, Aubry Jacques, Birklé Stéphane
Primary Institution: Centre de Recherche en Cancérologie de Nantes Angers, Inserm, Université de Nantes, Nantes Atlantique Universités, France
Hypothesis
The study investigates whether a monoclonal antibody specific for O-acetyl-GD2 can effectively target tumors without affecting peripheral nerves.
Conclusion
The monoclonal antibody 8B6 shows potent anti-tumor activity while avoiding cross-reactivity with peripheral nerves, suggesting it may reduce adverse side effects in treatment.
Supporting Evidence
- mAb 8B6 did not bind to peripheral nerves, indicating reduced toxicity.
- mAb 8B6 effectively inhibited tumor cell growth in vitro and in vivo.
- Treatment with mAb 8B6 resulted in a significant reduction in tumor size in mouse models.
- mAb 8B6 showed comparable efficacy to the anti-GD2 antibody 14G2a.
Takeaway
A special antibody can fight cancer without hurting nerves, which is good because other treatments can cause pain.
Methodology
The study used immunoperoxydase techniques to assess OAcGD2 distribution and tested the anti-tumor properties of mAb 8B6 in vitro and in vivo.
Potential Biases
Potential bias in the selection of tumor models and antibody specificity testing.
Limitations
The study primarily focuses on mouse models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website